Gender difference in vascular and platelet reactivity to thromboxane A2-mimetic U46619 and to endothelial dependent vasodilation in Zucker fatty (hypertensive, hyperinsulinemic) diabetic rats

Diabetes Research and Clinical Practice

Volumn 59, Issue 1, 2003, Pages 11-24

  Ajayi, A A ^a,b   Hercule, H ^a   Cory, James ^a   Hayes, B E ^a   Oyekan, A O ^a,b  

^a TEXAS SOUTHERN UNIVERSITY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Non insulin dependent diabetes mellitus; Platelet aggregation; Thromboxane A2 vascular reactivity; Zucker rats

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ACETYLCHOLINE; ANGIOTENSIN; ENDOTHELIN 1; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PHENYLEPHRINE; THROMBOXANE A2; VASOCONSTRICTOR AGENT; ANGIOTENSIN II; ENZYME INHIBITOR;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; FEMALE; HEMODYNAMIC MONITORING; HYPERINSULINEMIA; HYPERTENSION; HYPOTENSION; KIDNEY BLOOD FLOW; KIDNEY CORTEX; KIDNEY VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRESSOR RESPONSE; RAT; RAT STRAIN; SEX DIFFERENCE; THROMBOCYTE AGGREGATION; THROMBOSIS; VASCULAR ENDOTHELIUM; VASODILATATION; ANIMAL; BLOOD; DRUG EFFECT; KIDNEY CIRCULATION; METABOLISM; PATHOPHYSIOLOGY; SEXUAL DEVELOPMENT; VASCULARIZATION; ZUCKER RAT;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FEMALE; KIDNEY CORTEX; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; PHENYLEPHRINE; PLATELET AGGREGATION; RATS; RATS, ZUCKER; RENAL CIRCULATION; SEX CHARACTERISTICS; VASOCONSTRICTOR AGENTS; VASODILATION;

EID: 0037212867     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(02)00180-8     Document Type: Article

References (36)

1. Wingard D.L. The sex differential in morbidity, mortality, and life style. Annu. Rev. Public Health. 5:1984;433-458.
2. Rieves D., Wright G., Gupta G., Schacter E. Clinical trial (GUSTO-1 and INJECT) evidence for earlier death for men than women after myocardial infarction. Am. J. Cardiol. 85:2000;146-153.
3. Kolawole B.A., Ajayi A.A. Prognostic indices for intrahospital mortality in Nigerians with NIDDM diabetes: role of gender and hypertension. J. Diabetes Complications. 14:2000;84-89.
4. Damsgaard E.M., Froland A., Mogensen C.E. Over-mortality as related to age and gender in with established non-insulin-dependent diabetes mellitus. J. Diabetes Complications. 11:1997;77-80.
5. Asakawa H., Tokanaga K., Kawakami F. Comparison of risk factor of macrovascular complication, peripheral vascular disease, cerebral vascular disease, and coronary heart disease in Japanese type 2 diabetes mellitus patients. J. Diabetes Complications. 14:2000;307-313.
6. 2 receptor density and aggregation responses. Circulation. 91:1995;2742-2747.
7. 2 mimetic-induced coronary vasoconstriction in the Guinea pig. Eur. J. Clin. Invest. 24:1994;s50-s52.
8. 2/PGH2 receptor expression in human erythroleukemia [HEL] cells. Am. J. Physiol. 265:1993;E928-E934.
9. 2 receptors in rat aortic smooth cells. Circ. Res. 69:1991;638-643.
10. 2 receptors in rat aortic smooth cells. J. Cardiovasc. Pharmacol. 29:1997;311-315.
11. Karanian J.W., Ramwell P.W. Effect of gender and sex steroids on the contractile response to canine coronary and renal vessels. J. Cardiovasc. Pharmacol. 27:1996;312-319.
12. Davi G., Catalono I., Averna M., Notabartolo A.A., Strano A., Ciabattoni G., Patrono C. Thromboxane biosynthesis and platelet function in type II diabetes. N. Engl. J. Med. 322:1997;1769-1776.
13. Davi G., Gresele P., Voli F., et al. Diabetes mellitus, hypercholesterolemia and hypertension, but not vascular disease per se associated with persistent platelet activation in vivo: evidence derived from the study of peripheral arterial disease. Ciruclation. 96:1997;69-75.
14. Oskarsson H.J., Hofmeyer T.G. Diabetic human platelets release a substance that inhibits platelet-mediated vasodilation. Am. J. Physiol. 273:1997;H371-H379.
15. 2. Br. J. Pharmacol. 114:1995;1236-1249.
16. 2 of vasoconstriction induced by an alpha-agonist in mesenteric arterial bed from diabetic rats. Diabetologia. 41:1998;1410-1418.
17. Meeking D.R., Cummings M.H., Thorne S., et al. Endothelail dysfunction in type-2 diabetic subjects, with and without microalbuminuria. Diabetic Med. 16:1999;841-847.
18. Hercule H.C., Oyekan A.O. Role of NO and cytochrome P450 derived eicosanoids in ET-1 induced changes in intrarenal hemodynamics in rats. Am. J. Physiol. 279:2000;R2132-R2141.
19. Kurtz T.W., Morris R.C., Pershadsingh H.A. The Zucker fatty rat as a genetic model for obesity and hypertension. Hypertension. 13:1989;896-901.
20. Van Zweiten P.A., Kam K.L., Piji A.J., Hendrik N.G., Beenen O.H., Pfaffendorf M. Hypertensive diabetic rats in pharmacological studies. Pharmacol. Res. 33:1996;95-105.
21. Walker A.B., Dores J., Buckingham R.E., Savage M.W., Williams G. Impaired insulin-induced attenuation of noradrenaline-mediated vasoconstriction in insulin-resistant obese Zucker rats. Clin. Sci. 93:1997;235-241.
22. Zemel M.B., Reddy S., Sowers J.R. Insulin attenuation of vasoconstrictor response to phenylephrine in Zucker lean and obese rats. Am. J. Hypertens. 4:1991;537-539.
23. Schechter M., Merz C.N., Paul-Labrador M.J., Kaul S. Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease. J. Am. Coll. Cardiol. 35:2000;300-307.
24. Juttner C., Rodriguez M., Fragio C. Optimal conditions for simultaneous measurement of platelet aggregation and ATP secretion in canine whole blood. Res. Vet. Sci. 68:2000;27-32.
25. Kurekci A.E., Atay A.A., Sarici S.U., Zeybek C., Koseoglu V., Ozcan O. The effect of iron therapy on the whole blood platelet aggregation in infants with iron deficiency anemia. Thromb. Res. 97:2000;281-285.
26. Hui S.G., Ogle C.W. Thromboxane-mimetic U46619 causes depressor responses in anaesthetized rats. J. Pharm. Pharmacol. 54:1991;592-593.
27. Hui S.C., Ogle C.W. The hypotensive action of endoperoxide analogues in the rat. Arch. Int. Physiol. Biochim. Biophys. 101:1993;43-46.
28. Berhold H., Just A., Kirchheim H.R., Ehmke H.R. Interactions between nitric oxide and endogenous vasoconstrictors in the control of renal blood flow. Hypertension. 34:1999;1254-1258.
29. Forte P., Kneale B.J., Milne E., Chowienczyk, Johston A., Benjamin N., Ritter J.M. Evidence for a difference in nitric oxide biosynthesis between healthy women and men. Hypertension. 32:1998;730-734.
30. Steinberg H.O., Paradisi G., Cronin J., et al. Type II diabetes abrogate sex differences in endothelial function in premenopausal women. Circulation. 101:2000;2040-2046.
31. Verhagen A.M.G., Attia D.M.A., Koomamans H.A., Joles J.A. Male gender increases sensitivity to proteinuria induced by mild NOS inhibition in rats: role of sex hormones. Am. J. Physiol. 279:2000;F664-F670.
32. Huang A., Sun D., Koller A., Kaley G. 17 β-Estradiol restores endothelial nitric oxide release and shear stress in arterioles of male hypertensive rats. Circulation. 101:2000;94-97.
33. Uznova A.D., Ramey E.R., Ramwell P.W. Effect of testosterone, sex and age on experimentally induced arterial thrombosis. Nature. 261:1975;712-713.
34. Wu S.Q., Hopfner E.R., McNeil J.R., Wilson T.W., Gopalakrishnan V. Altered paracrine effect of endothelin in blood vessels of hyperinsulinemic, insulin resistant, obese rats. Cardiovasc. Res. 45:2000;994-1000.
35. Lim S.C., Cabellero A.E., Arora S., Smakowski P., Bashoff E.M., Brown F.M., Horton E.S., Veves A. The effect of hormonal replacement on the vascular reactivity and endothelial function of healthy individuals and individuals with type-2 diabetes. J. Clin. Endocrinol. Metab. 84:1999;4159-4164.
36. Weksler-Zangen S., Yagil C., Zangen D.H., Ornoy A., Jacob H.J., Yagil Y. The newly in bred Cohen diabetic rat: a non-obese, normolipemic, genetic model of diet induced type-2 diabetes, expressing sex differences. Diabetes. 50:(11):2001;2521-2529.